TSTickerStarGet alerts

VJET 10-Q filed 2026-11-16 | Key takeaways

VJET filed its 10-Q; the most relevant disclosure change is expanded Going concern: Company disclosed substantial doubt about its ability to continue as a going concern within 12 months from the date of issuance due to accumulated deficit of $329.6 million, working capital deficit of $3.2 million, and cash of $2.4 million. Customer concentration: Customer One represented 14% of revenue; Customer One represented 17% of revenue.

Share this story

Key takeaways

  • 5-7 ranked factual bullets

Key metrics

Total revenue from continuing operationsQ3 2026
$1,838 thousand
Total revenue from continuing operationsNine months ended September 30, 2026
$2,771 thousand
Net loss from continuing operationsQ3 2026
$1,853 thousand
Total net lossQ3 2026
$15,121 thousand
Total net lossNine months ended September 30, 2026
$20,117 thousand
Cash used in operating activitiesNine months ended September 30, 2026
$10,156 thousand
Cash and cash equivalentsSeptember 30, 2026
$2,393 thousand
Accumulated deficitSeptember 30, 2026
$329,623 thousand

Customer concentration

Customer OneQ3 2026
14%Share of revenue
Customer OneNine months ended September 30, 2026
17%Share of revenue
Customer OneSeptember 30, 2026
10%Share of accounts receivable
Customer TwoSeptember 30, 2026
14%Share of accounts receivable
Customer ThreeSeptember 30, 2026
18%Share of accounts receivable

Disclosure changes

  • Going concern

    Company disclosed substantial doubt about its ability to continue as a going concern within 12 months from the date of issuance due to accumulated deficit of $329.6 million, working capital deficit of $3.2 million, and cash of $2.4 million.

    Indicates significant financial distress and potential inability to fund operations without additional capital raises
  • Discontinued operations

    In September 2026, the company classified its VIVO and LockeT medical device businesses as discontinued operations and the related Disposal Group as held for sale, recognizing a $12.5 million noncash loss on impairment of assets held for sale.

    Significant strategic shift away from cardiac electrophysiology toward private aviation; large impairment charge impacts reported results
  • Business combination - FLYTE

    Company acquired 100% of FLYTE (private aviation) on March 9, 2026 for total purchase price of $14.8 million, recognizing $12.2 million in goodwill and $4.1 million in identifiable intangible assets.

    Transformative acquisition creating a new private aviation operating segment; substantial goodwill raises impairment risk
  • Series C and D Convertible Preferred Stock

    Company issued 12,874 shares of Series C Convertible Preferred Stock and 6,809 shares of Series D Convertible Preferred Stock during the nine months ended September 30, 2026; conversion prices subsequently reduced to $1.00 per share in October 2026.

    Significant dilution potential from preferred stock conversions at reduced prices
  • Series J Convertible Preferred Stock conversion price

    Series J conversion price reduced from $15.60 to $2.30 on October 1, 2026 and further to $1.00 on October 10, 2026, with stockholders approving the board's authority to reduce the price below $2.30.

    Substantial additional dilution to common stockholders from CEO's and affiliate's Series J preferred conversion
  • Reverse stock split

    1-for-10 reverse stock split effective October 5, 2026, reducing common shares outstanding from 14.4 million to 3.4 million; NYSE American rules limiting cumulative reverse stock split ratios may restrict near-term reverse splits.

    Reduces share count but also share price; potential violation of NYSE American continued listing standards

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow VJET in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert